Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Assets: 2019-2025

Historic Assets for 4D Molecular Therapeutics (FDMT) over the last 5 years, with Sep 2025 value amounting to $424.0 million.

  • 4D Molecular Therapeutics' Assets fell 29.81% to $424.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $424.0 million, marking a year-over-year decrease of 29.81%. This contributed to the annual value of $560.4 million for FY2024, which is 64.87% up from last year.
  • According to the latest figures from Q3 2025, 4D Molecular Therapeutics' Assets is $424.0 million, which was down 10.48% from $473.6 million recorded in Q2 2025.
  • In the past 5 years, 4D Molecular Therapeutics' Assets ranged from a high of $629.9 million in Q1 2024 and a low of $240.6 million during Q3 2021.
  • Over the past 3 years, 4D Molecular Therapeutics' median Assets value was $473.6 million (recorded in 2025), while the average stood at $466.0 million.
  • Its Assets has fluctuated over the past 5 years, first skyrocketed by 158.13% in 2024, then declined by 29.81% in 2025.
  • Over the past 5 years, 4D Molecular Therapeutics' Assets (Quarterly) stood at $353.5 million in 2021, then dropped by 25.92% to $261.8 million in 2022, then climbed by 29.81% to $339.9 million in 2023, then surged by 64.87% to $560.4 million in 2024, then fell by 29.81% to $424.0 million in 2025.
  • Its last three reported values are $424.0 million in Q3 2025, $473.6 million for Q2 2025, and $515.7 million during Q1 2025.